Introduction
Over the past two decades, antiretroviral therapy (ART) has transformed human immunodeficiency virus (HIV) into a long-term condition with normal life expectancy for people stable on treatment.
In 2016, 10,350 women living with HIV aged 45-56 (the age when women usually go through the menopause) attended HIV clinics in the UK. This is nearly half of all women attending for HIV care in the UK, and is five times the number in 2006. 1 As the number of women living with HIV reaching their midlife grows, we are beginning to understand the importance of addressing their healthcare needs during the menopause.
What is the impact of the menopause on women living with HIV?
• The menopause transition can have multidimensional impacts on the health and well-being of women living with HIV.
• There is conflicting evidence on the association between HIV and earlier age at menopause.
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• HIV infection is associated with an elevated risk of osteoporosis and cardiovascular disease, both of which are particularly increased among postmenopausal women living with HIV. 3, 4 • Women living with HIV aged 45-60 are more likely to report sexual problems than their HIV-negative counterparts.
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• Women living with HIV aged 45-60 report high levels of menopausal symptoms including hot flushes, urogenital symptoms and psychological symptoms.
• Women living with HIV may find it hard to distinguish HIV-related symptoms from menopausal symptoms, leading to anxiety.
• Among women living with HIV, menopausal symptoms are associated with psychological distress 1 and decreased adherence to ART (which is important in terms of women's own health and also the prevention of HIV transmission to others). 5 • Use of systemic and topical hormone replacement therapy (HRT) is very low among women living with HIV (8% and 3%, respectively) despite the high prevalence of symptoms.
What are the key points about managing the menopause in women living with HIV?
• National HIV guidelines recommend baseline assessment of menstrual cycle within HIV clinics, and annual review thereafter, as well as assessment of menopausal symptoms in those aged >45 (or those assessed as being postmenopausal). What support do women living with HIV need through the menopause?
• Nearly half of women living with HIV in a recent national study stated they did not have enough information about the menopause, leaving many feeling under-prepared.
• Midlife women living with HIV should be provided information on menopause and symptom management (see resources for HIV specific leaflets 
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